Related Experiment Video
Updated: Sep 13, 2025

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
Published on: September 13, 2018
Oxytocin Receptor Regulates the Hippo/YAP Axis to Drive Hepatocarcinogenesis
Huijie Yang1,2, Jiayao Cui1,2, Peng Su3
1Xinxiang Key Laboratory of Tumor Migration and Invasion Precision Medicine, School of Medical Technology, Xinxiang Medical University, Xinxiang, P.R. China.
Abstract:
Dysregulation of Hippo signaling, especially the downstream effector YAP, is a critical driver of hepatocellular carcinoma (HCC). Therefore, identifying therapeutic targets to block Hippo signaling could help improve survival outcomes for patients with HCC. In this study, we conducted an unbiased siRNA screen on G protein-coupled receptors targeted by drugs approved in the United States and strongly associated with the Hippo/YAP pathway and identified the oxytocin receptor (OXTR) as an important activator of the Hippo/YAP axis in HCC. The OXTR was correlated with the Hippo gene signature and poor survival outcomes in HCC, and OXTR activation promoted HCC progression through the Hippo/YAP axis. The OXTR antagonist atosiban blocked the growth of HCC in xenograft, patient-derived explant, organoid, and MST1/2 double-knockout mouse models. Molecular studies revealed that activation of the OXTR facilitated YAP dephosphorylation, nuclear accumulation, and transcriptional activation in HCC. OXTR interacted with Gαq/11 at several important sites (R137, I141, and I227) and induced YAP activation through the Gαq/11/Rho-associated protein kinase/LATS axis. Chromatin immunoprecipitation assays showed that YAP bound to the enhancer region of the OXTR and facilitated its transcription, creating a positive feedback loop. Together, this study uncovered the interplay between Hippo signaling and the OXTR pathway in hepatocarcinogenesis and established OXTR inhibition with atosiban as a promising strategy for treating HCC.
Significance:
The FDA-approved oxytocin receptor antagonist atosiban can ameliorate Hippo signaling dysfunction in liver cancer to suppress tumor growth, providing an effective and rapidly translatable therapy for hepatocellular carcinoma.
Insights
Dysregulation of the Hippo-YAP pathway drives liver cancer. Researchers identified the oxytocin receptor (OXTR) as a key activator, finding its antagonist, atosiban, effectively inhibits hepatocellular carcinoma (HCC) growth.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Hippo signaling pathway dysregulation, particularly YAP, is a key driver of hepatocellular carcinoma (HCC).
- Targeting the Hippo pathway offers potential therapeutic strategies for improving HCC patient survival.
Purpose of the Study:
- To identify G-protein coupled receptors (GPCRs) associated with the Hippo/YAP pathway in HCC.
- To investigate the role of the oxytocin receptor (OXTR) in HCC progression and its potential as a therapeutic target.
Main Methods:
- Unbiased siRNA screen of US-approved GPCR-targeted drugs.
- Correlation analysis of OXTR expression with Hippo gene signature and patient survival.
- In vivo and in vitro functional assays using xenograft, patient-derived explant, organoid, and mouse models.
- Molecular analyses including YAP dephosphorylation, nuclear accumulation, and transcriptional activity assays.
- Investigation of OXTR interaction with Gαq/11 and downstream signaling (ROCK/LATS axis).
- Chromatin immunoprecipitation (ChIP) assays to assess YAP binding to OXTR enhancer regions.
Main Results:
- OXTR was identified as a significant activator of the Hippo/YAP axis in HCC.
- OXTR expression correlated with poor survival outcomes in HCC patients.
- The OXTR antagonist atosiban demonstrated efficacy in inhibiting HCC growth across multiple preclinical models.
- OXTR activation promotes HCC progression by facilitating YAP dephosphorylation and nuclear accumulation via the Gαq/11/ROCK/LATS pathway.
- A positive feedback loop exists where YAP enhances OXTR transcription.
Conclusions:
- The oxytocin receptor (OXTR) plays a critical role in hepatocarcinogenesis by activating the Hippo/YAP pathway.
- Inhibition of OXTR using atosiban represents a promising therapeutic strategy for hepatocellular carcinoma (HCC).
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Hedgehog Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Regulation of Food Intake
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...

